MOSES-assisted versus conventional holmium laser enucleation of the prostate for benign prostatic hyperplasia: a pooled study.
- 1Department of Urology, People's Hospital of Deyang City, Chengdu University of Traditional Chinese Medicine, Deyang, China.
- 2Department of Urology, Deyang Hospital Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Deyang, China.
Abstract
With the widespread adoption of holmium laser enucleation of the prostate (HoLEP), increasing attention has focused on whether pulse-modulation technologies can further improve procedural efficiency and perioperative outcomes. We therefore conducted an updated systematic review and meta-analysis comparing MOSES-assisted HoLEP (MoLEP) with conventional HoLEP for benign prostatic hyperplasia (BPH). PubMed, Embase, Web of Science, and the ClinicalTrials.gov were searched through September 2026 for comparative studies evaluating MoLEP versus conventional HoLEP. Study selection and data extraction were performed according to predefined criteria. Pooled analyses were conducted using R (version 4.4.1), with subgroup and sensitivity analyses undertaken where appropriate. Ten studies comprising 3,177 patients (1,599 MoLEP and 1,578 conventional HoLEP) were included. MoLEP was associated with shorter enucleation time (MD -7.45 min, 95% CI -11.05 to -3.85; P < 0.001), hemostasis time (MD -3.79 min, 95% CI -5.93 to -1.65; P < 0.001), and operative time (MD -12.09 min, 95% CI -18.01 to -6.18; P < 0.001). No significant between-group differences were observed in enucleated weight (MD 1.01 g, 95% CI -3.20-5.21; P = 0.639), catheterization time (SMD -0.13, 95% CI -0.35-0.09; P = 0.238), or length of stay (SMD -0.23, 95% CI -0.52-0.05; P = 0.113). MoLEP was associated with a generally lower incidence of postoperative complications than conventional HoLEP (P < 0.001). Regarding functional outcomes, statistically significant between-group differences were observed in PVR at 1 and 6 months, QoL at 3 months, and IPSS at 6 months, whereas other functional outcomes did not differ significantly between groups. The current evidence suggests that MoLEP may improve perioperative efficiency and reduce postoperative complications, while early functional outcomes remain broadly comparable with conventional HoLEP. Further high-quality studies with longer follow-up are needed to confirm these potential benefits. ID: CRD420251177474.
Related
- Holmium laser enucleation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
- Comparison of low-power long-pulse width and high-power short-pulse width holmium laser enucleation of the prostate for benign prostatic hyperplasia: a retrospective study
- Function-preserving plasma kinetic enucleation of the prostate with bladder neck and 12 o'clock urethral mucosal preservation for large-volume benign prostatic hyperplasia: a single-center retrospective case series.
- Incidental Prostate Cancer in Patients Undergoing Surgery for Benign Prostatic Hyperplasia: A Predictive Model
- Who should be considered for prostate artery embolization: revisiting the urologic guidelines based on results from over 300 patients with benign prostatic hyperplasia.
BibTeX
@article{wang2026mosesassisted,
title = {{MOSES-assisted versus conventional holmium laser enucleation of the prostate for benign prostatic hyperplasia: a pooled study.}},
author = {Puze Wang and Jinze Li and Youlong Huili and Yuchang Tian and Chongzhou Liao and Dong Ren and Huawei Liu and Dong Lv and Lei Xu},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1946428},
url = {https://europepmc.org/article/MED/42952613},
note = {CC BY},
}
RIS
TY - JOUR
TI - MOSES-assisted versus conventional holmium laser enucleation of the prostate for benign prostatic hyperplasia: a pooled study.
AU - Puze Wang
AU - Jinze Li
AU - Youlong Huili
AU - Yuchang Tian
AU - Chongzhou Liao
AU - Dong Ren
AU - Huawei Liu
AU - Dong Lv
AU - Lei Xu
PY - 2026
DA - 2026/10/14
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1946428
UR - https://europepmc.org/article/MED/42952613
AB - With the widespread adoption of holmium laser enucleation of the prostate (HoLEP), increasing attention has focused on whether pulse-modulation technologies can further improve procedural efficiency and perioperative outcomes. We therefore conducted an updated systematic review and meta-analysis comparing MOSES-assisted HoLEP (MoLEP) with conventional HoLEP for benign prostatic hyperplasia (BPH). PubMed, Embase, Web of Science, and the ClinicalTrials.gov were searched through September 2026 for comparative studies evaluating MoLEP versus conventional HoLEP. Study selection and data extraction were performed according to predefined criteria. Pooled analyses were conducted using R (version 4.4.1), with subgroup and sensitivity analyses undertaken where appropriate. Ten studies comprising 3,177 patients (1,599 MoLEP and 1,578 conventional HoLEP) were included. MoLEP was associated with shorter enucleation time (MD -7.45 min, 95% CI -11.05 to -3.85; P < 0.001), hemostasis time (MD -3.79 min, 95% CI -5.93 to -1.65; P < 0.001), and operative time (MD -12.09 min, 95% CI -18.01 to -6.18; P < 0.001). No significant between-group differences were observed in enucleated weight (MD 1.01 g, 95% CI -3.20-5.21; P = 0.639), catheterization time (SMD -0.13, 95% CI -0.35-0.09; P = 0.238), or length of stay (SMD -0.23, 95% CI -0.52-0.05; P = 0.113). MoLEP was associated with a generally lower incidence of postoperative complications than conventional HoLEP (P < 0.001). Regarding functional outcomes, statistically significant between-group differences were observed in PVR at 1 and 6 months, QoL at 3 months, and IPSS at 6 months, whereas other functional outcomes did not differ significantly between groups. The current evidence suggests that MoLEP may improve perioperative efficiency and reduce postoperative complications, while early functional outcomes remain broadly comparable with conventional HoLEP. Further high-quality studies with longer follow-up are needed to confirm these potential benefits. ID: CRD420251177474.
SN - 2296-858X
ER -